Positron Corporation Enters Industry Partnership Agreement with MedAxiom
MWN-AI** Summary
Positron Corporation has announced a strategic industry partnership with MedAxiom, a prominent organization in the cardiovascular sector, dedicated to enhancing organizational performance within the medical field. Based in Buffalo, NY, Positron, known for its advanced molecular imaging technology and specialized in PET and PET-CT systems, aims to boost the adoption of its imaging solutions through this collaboration.
MedAxiom’s extensive network of physicians, clinicians, and healthcare administrators positions Positron to gain critical insights and enhance its visibility within the cardiovascular community. As an industry partner, Positron will have access to a wealth of resources and collaborative opportunities that will support the wider implementation of its PET-CT technology. Joe Sasson, MedAxiom’s executive vice president of Ventures, emphasized the transformative impact of cardiac PET in improving healthcare outcomes, expressing enthusiasm for the partnership with Positron to advance educational initiatives and operational insights within the cardiovascular field.
Adel Abdullah, President of Positron, highlighted the importance of forming partnership ties with industry leaders like MedAxiom, which is recognized for its commitment to excellence in cardiovascular care. This collaboration is expected to accelerate the adoption of Positron’s imaging solutions, particularly as the demand for advanced diagnostic tools in cardiovascular medicine continues to grow.
Positron is focusing on expanding its footprint in both cardiac and oncology PET modalities, promising to deliver cutting-edge imaging technology, including a new 4D molecular imaging device, the Affinity PET-CT 4D 64-Slice. This partnership not only enriches Positron's market strategy but also signifies a substantial step towards enhancing patient care in nuclear cardiology. For more information, Positron has urged interested parties to visit their website.
MWN-AI** Analysis
Positron Corporation’s recent partnership with MedAxiom marks a significant milestone for the company, positioning it at the forefront of advancements in nuclear cardiology. This collaboration grants Positron access to an expansive network comprised of leading cardiovascular professionals and organizations, which is critical for accelerating the adoption of its PET and PET-CT imaging technologies.
The cardiac PET market is gaining momentum due to its demonstrated effectiveness in enhancing diagnostic accuracy for coronary artery disease. MedAxiom’s reputation as a trusted authority in cardiovascular performance solutions opens avenues for Positron to enhance its market footprint and promote its innovative Affinity PET-CT 4D 64-Slice system.
Investors should view this partnership as a pivotal development. With MedAxiom's support in terms of clinical insights and market intelligence, Positron is better equipped to address the growing demands for advanced diagnostic tools in the healthcare sector. The collaboration not only facilitates knowledge exchange but also provides opportunities for joint ventures that could lead to further innovations and enhanced patient care solutions.
Moreover, Positron's commitment to transforming cardiovascular care through its advanced imaging systems positions it favorably in an industry increasingly focused on high-quality and cost-effective healthcare solutions. The potential growth in the oncology imaging segment, due to the capabilities of its PET-CT systems, suggests additional avenues for revenue expansion.
However, prospective investors should remain cautious. The market dynamics may be influenced by regulatory changes, technological advancements from competitors, and potential barriers to entry in new markets. While the collaboration with MedAxiom provides a strong strategic advantage, investors should conduct thorough due diligence and consider the associated risks.
In conclusion, Positron’s strategic alliance with MedAxiom represents a compelling opportunity, positioning the company for growth in the evolving landscape of nuclear cardiology, but investors must remain vigilant and consider the broader market variables.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Buffalo, NY, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging technology company specializing in PET and PET-CT imaging systems and clinical services is pleased to announce a partnership with MedAxiom, the cardiovascular community’s premier source for organizational performance solutions.
MedAxiom is recognized nationwide for its extensive network of physicians, clinicians, and administrators, and for driving innovation and best practices that improve outcomes and performance across cardiovascular medicine.
As a MedAxiom industry partner, Positron is connected to the nation’s leading cardiovascular organizations, gaining valuable insights and exposure that advance the adoption of the PET modality. This collaboration provides unparalleled access to hundreds of organizations and thousands of physicians, clinicians, and thought leaders who are driving advancements in nuclear cardiology. Engagement with the MedAxiom community will provide Positron with market intelligence, clinical insight, and opportunities for collaboration that support broader adoption of PET-CT technology and improved patient care.
"Cardiac PET is transforming cardiovascular care, and its rapid growth shows no signs of slowing,” said Joe Sasson, PhD, MedAxiom’s executive vice president of Ventures and chief commercial officer. “As programs increasingly adopt this advanced diagnostic tool in pursuit of high-quality care, MedAxiom looks forward to partnering with Positron to bring valuable education, innovative solutions, and meaningful operational insights to our community of cardiovascular leaders."
Adel Abdullah, President of Positron, commented, “MedAxiom is a trusted leader in cardiovascular excellence, and we are proud to join such a valuable network. This partnership connects Positron with a community at the forefront of transforming cardiovascular care through the PET modality. It is an exciting time for both Positron and the nuclear cardiology field, and MedAxiom will be a tremendous resource helping us expand our user base and accelerate adoption of our imaging solutions.”
About Positron Corporation
Positron Corporation is a medical technology company that co-develops, manufactures, and sells state-of-the-art PET and PET-CT imaging systems and clinical services to nuclear medicine healthcare providers throughout North America.
Positron specializes in the field of cardiac Positron Emission Tomography (PET) imaging, the gold standard in cardiac diagnostics. Positron’s innovative PET/PET-CT technologies, clinical services and practice solutions enables healthcare providers to accurately diagnose coronary artery disease and improve patient outcomes while practicing cost effective medicine.
Positron's PET and PET-CT imaging systems and distinct market position are substantial advantages unique to Positron that will facilitate the adoption of cardiac PET and the growth of the nuclear imaging market. Positron will soon offer a state-of-the-art PET-CT 4D molecular imaging device in the Affinity PET-CT 4D 64-Slice. Positron’s PET-CT(s) will enable nuclear cardiologists to utilize the full capabilities of molecular imaging and nuclear medicine. Positron’s PET-CT systems will also enable the Company to fully service and meet the demands of the vast oncology imaging segment of nuclear medicine.
Positron is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to imaging specialists and will continue to advance its technology through its co-developer, supplier, and R&D venture with Shenyang Intelligent Neuclear Technology Co. a subsidiary of Neusoft Medical Systems.
Please visit the Company’s website at: www.positron.com .
Forward-Looking Statements
This press release contains statements which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Positron Corporation, and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results even if new information becomes available in the future.
FOR FURTHER INFORMATION, please visit the company’s website at www.positron.com , or contact: investor@positron.com
Investor Relations Contact:
Skyline Corporate Communications Group, LLC
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
info@skylineccg.com
FAQ**
How does the partnership between MedAxiom and Positron Corp. (POSC) enhance the adoption of cardiac PET-CT technology in the healthcare market?
What specific outcomes and performance improvements does Positron Corp. (POSC) aim to achieve through its collaboration with MedAxiom?
How will the new PET-CT 4D molecular imaging device from Positron Corp. (POSC) impact the landscape of cardiac and oncology imaging?
What market intelligence and clinical insights does Positron Corp. (POSC) expect to gain from its engagement with MedAxiom’s extensive network?
**MWN-AI FAQ is based on asking OpenAI questions about Positron Corp. (OTC: POSC).
NASDAQ: POSC
POSC Trading
-3.9% G/L:
$1.97 Last:
24,624 Volume:
$2.096 Open:
